Bayer AGs expansion into new drug modalities has caught the eye, not least the launch of a dedicated cell and gene therapy unit, but the German major needs its recent launches to succeed and the late-stage pipeline to progress so that those earlier innovative projects can flourish.
That is the view of pharma R&D chief Christian Rommel who took up the post just shy of a year ago, having joined Bayer from Roche Holding AG where he was global head of oncology research and early development. Speaking to Scrip from the virtual J.P
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?